Immix Biopharma annual return on equity
2021
2022
2023
2024
2025
Immix Biopharma Return on Equity (ROE) Growth & History (IMMX)
Immix Biopharma's return on equity was −55.00% for fiscal 2025.
View full Immix Biopharma company overviewImmix Biopharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −55.00% | +90.76 pp |
| 2024 | 2024-12-31 | −145.76% | −41.41 pp |
| 2023 | 2023-12-31 | −104.35% | −51.51 pp |
| 2022 | 2022-12-31 | −52.84% | +314.96 pp |
| 2021 | 2021-12-31 | −367.80% | — |
Immix Biopharma quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −7.38% | +85.59 pp |
| Q1 2026 | 2026-03-31 | −11.32% | +28.45 pp |
| Q4 2025 | 2025-12-31 | −20.94% | +10.30 pp |
| Q3 2025 | 2025-09-30 | −117.44% | −82.94 pp |
| Q2 2025 | 2025-06-30 | −92.97% | −76.01 pp |
| Q1 2025 | 2025-03-31 | −39.77% | −16.04 pp |
| Q4 2024 | 2024-12-31 | −31.25% | −3.11 pp |
| Q3 2024 | 2024-09-30 | −34.50% | −8.56 pp |
| Q2 2024 | 2024-06-30 | −16.96% | +11.65 pp |
| Q1 2024 | 2024-03-31 | −23.73% | −3.84 pp |
| Q4 2023 | 2023-12-31 | −28.14% | −2.73 pp |
| Q3 2023 | 2023-09-30 | −25.94% | −17.14 pp |
| Q2 2023 | 2023-06-30 | −28.61% | −20.34 pp |
| Q1 2023 | 2023-03-31 | −19.89% | −12.82 pp |
| Q4 2022 | 2022-12-31 | −25.41% | +317.82 pp |
| Q3 2022 | 2022-09-30 | −8.81% | — |
| Q2 2022 | 2022-06-30 | −8.28% | — |
| Q1 2022 | 2022-03-31 | −7.08% | — |
| Q4 2021 | 2021-12-31 | −343.23% | — |
Immix Biopharma return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Immix Biopharma's return on equity increased from −367.80% to −55.00%, a change of +312.79 percentage points. The latest reported quarter, Q2 2026, shows −7.38%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immix Biopharma source filings ↗